EMA logs more clotting cases after AstraZeneca shot, death rate lower
Reuters
Published May 28, 2021 01:02PM ET
Updated May 28, 2021 01:32PM ET
(Reuters) - A total of 316 cases of rare blood clots with low platelets have been recorded in adults who received AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine in the European Economic Area, an executive of the region's drug regulator said.
The figure as of Thursday includes 174 new reports since the European Medicines Agency (EMA) provided an update in April, Georgy Genov, the chief of the watchdog's safety monitoring operations, said during a briefing on Friday.
The EMA has been looking into cases of thrombosis with thrombocytopenia syndrome (TTS) since March and has found a possible link to the vaccine developed with Oxford University, Vaxzevria, and to Johnson & Johnson (NYSE:JNJ)'s single-dose shot.
It has, however, maintained that overall benefits of both the vaccines outweigh any risks posed by them.
Genov said a further 19 million people had received the first dose of Vaxzevria in the EEA since the April update, adding that the frequency of TTS has not changed - it is still extremely rare - but the fatality rate following symptoms has decreased.
He said the drop in death rates possibly indicated that awareness among those vaccinated and those administering the vaccine and treating patients had gone up, leading to early diagnosis and treatment.
The European Economic Area comprises the 27 countries in the European Union, plus Iceland, Norway and Liechtenstein.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.